ELVN — Enliven Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.31bn
- $832.23m
- 40
- 30
- 82
- 50
Annual income statement for Enliven Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 41.7 | 51.4 | -0.73 | 83.5 | 105 |
| Operating Profit | -41.7 | -51.4 | 0.73 | -83.5 | -105 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -41.4 | -51.4 | 1.58 | -71.6 | -88.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -41.4 | -51.4 | 1.49 | -71.6 | -89 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -41.4 | -51.4 | 1.49 | -71.6 | -89 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -49.2 | -51.4 | 1.49 | -71.6 | -89 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -14.1 | -9.49 | -3.2 | -2.01 | -1.89 |